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Abstract
Objective—People living with HIV (PLWH) have chronic immune activation and increased 
cardiovascular disease (CVD) risk. Activation of monocytes and T lymphocytes causes up-
regulation of glucose transporter-1 (GLUT1) for efficient function. PLWH have an increased 
percentage of GLUT1-expressing monocytes and T lymphocytes, but it is unclear if these cells are 
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associated with CVD. We evaluated expression of GLUT1 and CD38 on monocyte and T 
lymphocyte populations from HIV-infected women with subclinical CVD.
Methods—Participants with >75th percentile (n=15) and <25th percentile (n=15) age-adjusted 
intima-media thickness (IMT) at the right common carotid artery and bifurcation were identified 
from the Women's Interagency HIV Study. Groups were matched by age, race/ethnicity, smoking 
status, and CD4 count. All women were receiving suppressive antiretroviral therapy except for one 
high and one low IMT participant. Monocyte and T lymphocyte populations were evaluated for 
GLUT1 and CD38 expression using flow cytometry.
Results—Intermediate monocytes from high IMT women had significantly increased expression 
of GLUT1 (310 MFI vs. 210 MFI, p=0.024) (66.4% vs. 48.5%, p=0.031) and CD38 (339 MFI vs. 
211 MFI, p=0.002) (10.5% vs. 3.8%, p=0.0002) compared to women with low IMT. High and low 
IMT participants showed no differences in GLUT1 or CD38 expression on classical monocytes, 
non-classical monocytes, CD4+ and CD8+ T lymphocytes.
Conclusion—GLUT1-expressing intermediate monocytes are elevated in HIV-infected women 
with subclinical CVD. These cells may contribute to development of CVD in PLWH and could be 
a novel target to limit inflammation.
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Introduction
Persons living with HIV (PLWH) can be effectively treated with combination antiretroviral 
therapy (cART); yet their lifespans may still be shorter than those of HIV-uninfected persons 
[1]. In both high and lower income settings the causes of death among PLWH are shifting 
from AIDS-related to non-AIDS-related diseases such as cardiovascular disease (CVD) 
[1,2].
CVD is a metabolic and inflammatory disease associated with activated monocytes and T 
lymphocytes [3,4]. The metabolism of monocytes and T lymphocytes can change 
dramatically upon activation, with both activated cell types upregulating surface expression 
of glucose transporter-1 (GLUT1) for efficient function [5–8]. The percentage of GLUT1-
expressing monocytes and CD4 T lymphocytes is elevated in both untreated and cART-
treated PLWH when compared to uninfected persons [5,6]. This increase in GLUT1-
expressing monocytes and T lymphocytes could be an important source of inflammation 
leading to CVD as GLUT1-expressing mononuclear phagocytes have been shown to express 
proinflammatory cytokines [9]. It remains unclear if these GLUT1-expressing cells are 
associated with CVD in PLWH.
Monocytes are composed of several populations that can be characterized by the differential 
expression of CD14 and CD16 surface markers [10]. Classical monocytes (CD14++CD16-) 
express high levels of CD14, lack CD16, and represent the majority of monocytes in the 
blood. CD16-expressing monocytes are associated with increased production of TNF-α and 
are considered to be inflammatory. CD16-expressing monocytes are further subdivided into 
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non-classical monocytes (CD14+CD16++) and intermediate monocytes (CD14++CD16+). 
The intermediate monocyte population, while only recently considered to be a distinct subset 
of monocytes, has been increasingly associated with inflammation as it relates to the 
increased risk of CVD [11]; increased levels of TNF-α [12], IL-1β [13], and D-dimer [14]; 
and a distinct role in antigen presentation and processing [15].
Both activated CD4+ and CD8+ T lymphocytes have been pathogenetically implicated in 
HIV –infected people with CVD. Activated CD8+ T lymphocytes have previously been 
linked to markers of CVD inflammation [16] and Kaplan et. al. identified an association 
between activated CD4+ T lymphocytes and the presence of carotid artery plaques [17]. 
However, other reports have shown that T lymphocyte activation was not associated with 
serious non-AIDS events, including CVD outcomes [18].
The aim of this study was to evaluate the expression of GLUT1 on monocyte and T 
lymphocyte populations in HIV-infected women with subclinical CVD to explore if it could 
contibute to CVD in PLWH.
Methods
High and low IMT groups were identified from the Women's Interagency HIV Study 
(WIHS), a longitudinal cohort study of women with HIV and a risk-set matched control 
group. The high IMT group was defined as having >75th percentile intima-media thickness 
(IMT) measured at the right common carotid artery (CCA) and bifurcation (BIF) (CCA-IMT 
range 0.779-1.488 mm, BIF-IMT range 0.920-1.621 mm) and low IMT group was defined 
as having <25th percentile intima-media thickness at the CCA and BIF (CCA-IMT 
0.591-0.704 mm, BIF-IMT 0.614-0.772 mm). IMT was measured by high resolution B-
mode carotid artery ultrasound of the far wall of the right common carotid artery (CCA) and 
bifurcation (BIF) according to the procedure of Hodis et al. [19]. IMT values were first age-
adjusted because IMT and age are correlated. Groups were then matched by age, race/
ethnicity, smoking status, and CD4 count. Thereafter, 15 pairs were identified, giving a total 
of thirty (30) participants. All participants except one case and one control were virally 
suppressed on cART.
Blood samples were collected in the WIHS at semiannual visits [20]. Twenty-seven (27) 
participants were fasting at the time of sample collection. The samples used in this study 
were collected between April 2012 and March 2015. Peripheral blood mononuclear cells 
(PBMCs) were processed and stored in liquid nitrogen at a minimum 6 million cells per 
aliquot [20]. Plasma (never previously thawed) was also collected from women at these 
visits and stored at -20°C.
Cryopreserved PBMCs were rested for 2 hours at 37°C prior to staining in RPMI-1640 
medium (Corning CellGro) containing 10% fetal bovine serum (Gemini Bio-Products), 200 
IU penicillin/200 μg/mL streptomycin (Sigma Aldrich) and 2 mM L-glutamine (Sigma 
Aldrich). PBMCs were stained on ice for LIVE/DEAD Fixable Aqua Stain (Life 
Technologies; catalog L34957), CD3–BV421 (BD Biosciences; catalog 562426), CD4–PE-
CF594 (BD Biosciences; catalog 562281), CD8–APC-H7 (BD Biosciences; catalog 
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560179), CD38–APC (BD Biosciences; catalog 555462), HLA-DR–PE-Cy7 (BD 
Biosciences; catalog 560651), CD14–BV786 (BD Biosciences; catalog 563698), CD16–
BV650 (BD Biosciences; catalog 563692), CD19–AF700 (BD Biosciences; catalog 
557921), CD56–AF700 (BD Biosciences; catalog 557919) and GLUT1–PE (R&D Systems; 
catalog FAB1418P). Antibody concentrations were selected according to the manufacturer's 
recommendation. Cells were acquired on an LSRFortessa II (BD Biosciences) and analyzed 
using FlowJo Software (Tree Star Inc.). Samples were run daily with matched samples from 
the high and low IMT group on each day. SPHERO™ rainbow calibration particles 
(Spherotech Inc.; catalog RCP-30-5A) were used each day to check the sensitivity and 
linearity of the flow cytometer. The cryopreservation and thawing process was previously 
shown to have no effect on the expression of GLUT1 on cells [5].
T lymphocyte and monocyte subpopulations were identified by flow cytometry 
(Supplemental Figure 1). Briefly, scatter properties were used to determine initial monocyte 
and lymphocyte gates which were then gated to select live cells. CD3, CD4 and CD8 
expression were used to distinguish T lymphocyte populations, while CD3, CD56 and CD19 
were used to exclude T lymphocytes, NK cells and B cells, respectively, from the initial 
monocyte gate. Monocyte subpopulations were then distinguished using CD14 and CD16 
expression. CD38 was used as an activation marker of T lymphocytes and monocytes 
[21,22]. Histograms depicting the expression of GLUT1 and CD38 on monocyte populations 
are shown in Supplemental Figure 1.
For cytokine detection, plasma was thawed and ELISA was performed according to the 
manufacturer's instructions for IL-6 (Human IL-6 Quantikine HS ELISA Kit, catalog 
HS600B; MDD < 0.70 pg/mL), sCD14 (Human sCD14 Quantikine ELISA Kit, catalog 
DC140; MDD = 125pg/mL) and sCD163 (Human CD163 Quantikine ELISA Kit, catalog 
DC1630; MDD = 0.177 ng/mL). All ELISA kits were obtained from R&D Systems.
The non-parametric Mann Whitney U test was used for comparison of unpaired data. The 
Spearman rank test was used to test for correlation. The Fisher's exact test was used for 
comparison of categorical data. P values less than 0.05 were considered significant. All 
analyses were conducted using GraphPad Prism (Graph Pad Software, version 6.07).
Results
Demographic and clinical characteristics of participants are summarized in Table 1. High 
IMT participants had significantly greater CCA-IMT (0.893 mm vs. 0.653 mm, p<0.0001) 
and BIF-IMT (0.984 mm vs. 0.701 mm, p<0.0001) than participants with low IMT. 
Participants with high IMT had higher hemoglobin A1c (6.0% vs. 5.5%, p=0.022), serum 
insulin (19.5 mIU/mL vs. 13.0 mIU/mL, p=0.039), triglycerides (138.5 mg/dL vs. 91.5 
mg/dL, p=0.043), systolic blood pressure (126 mmHg vs. 114 mmHg, p=0.036) and lower 
HDL levels (50.0 mg/dL vs. 60.5 mg/dL, p=0.037) than women with low IMT. Plasma levels 
of sCD14, IL-6 and sCD163 showed no difference between women with high or low IMT.
The percentage of intermediate monocytes expressing GLUT1 (66.4% vs. 48.5%, p=0.031) 
was higher in women with high IMT compared to those with low IMT while there were no 
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differences between groups for non-classical monocytes, classical monocytes, and CD4 and 
CD8 T lymphocytes (Fig. 1a & b). Also, the expression of GLUT1 on intermediate 
monocytes was higher in women with high IMT (310 MFI vs. 210 MFI, p=0.024) with no 
differences in GLUT1 expression between groups for other monocyte subsets and CD4 and 
CD8 T lymphocytes (Fig. 1c & d). When assessing all samples, IMT correlated with both 
the percentage of GLUT1-expressing intermediate monocytes (r=0.390, p=0.037) and 
expression of GLUT1 on intermediate monocytes (r=0.398, p=0.032). There were no 
differences in the proportions of classical, non-classical and intermediate monocytes and 
CD4 and CD8 T lymphocytes between the two groups. The percentage of CD38 expressing 
intermediate monocytes was significantly elevated when comparing the high and low IMT 
groups (10.5% vs. 3.8%, p=0.0002) (Fig. 1e). There were no differences in the percentages 
of CD4 and CD8 T lymphocytes expressing CD38 when comparing high and low IMT 
groups (Fig. 1f). Similar to CD38 expression, the percentage of intermediate monocytes 
expressing both CD38 and GLUT1 was significantly higher in the high IMT group (15.5% 
vs. 4.5%, p=0.0008) (Fig. 1g), with no differences observed between groups for T 
lymphocytes (Fig. 1h). These data suggest an immunometabolic basis for monocyte 
activation.
Discussion
GLUT1 expression has been previously shown to be associated with activation of T 
lymphocytes and monocytes in treated and untreated HIV infection [5,6]. For CD4 T 
lymphocytes, the percentage of cells expressing GLUT1 is increased during untreated HIV 
infection; however, during treated HIV infection these levels are significantly decreased 
compared to untreated persons [5]. In contrast, the percentage of GLUT1-expressing 
monocytes is similar between untreated and treated HIV infection, indicating that even 
during treated HIV infection monocytes remain activated [6]. Consistent with these studies, 
we found that GLUT1-expressing intermediate monocytes, but not GLUT1-expressing T 
lymphocyte populations, are associated with subclinical CVD in a predominantly cART-
treated population of HIV-infected women. Our results are also consistent with several 
recent reports showing that markers of activated monocytes are associated with CVD in 
PLWH [18,23,24].
The percentages of pro-inflammatory intermediate and non-classical monocyte 
subpopulations are similar between PLWH with uncontrolled viremia and HIV-uninfected 
persons with acute coronary syndrome [25], indicating that PLWH may have an 
inflammatory monocyte profile that contributes to a pro-atherogenic state. This is consistent 
with the data presented here demonstrating a higher percentage of GLUT1-expressing 
intermediate monocytes from HIV-infected women with high IMT compared to those with 
low IMT. These proinflammatory GLUT1-expressing intermediate monocytes are activated, 
as GLUT1 expression correlated with the activation marker CD38. This correlation between 
GLUT1 and CD38 suggests an interrelationship between metabolism and monocyte 
activation.
Immune stimuli present during HIV infection, such as the microbial translocation product 
LPS, can activate monocytes [26], causing an upregulation of GLUT1 [26,27]. Although we 
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did not examine the cause of differential intermediate monocyte GLUT1 expression for the 
two IMT groups in this study, it is possible that increased levels of monocyte stimuli in some 
HIV-infected persons could lead to increased monocyte activation and GLUT1 expression 
[28,29]. We previously showed that monocytes stimulated with LPS upregulate GLUT1 
expression and produce increased levels of TNF-α compared to unstimulated monocytes [6]. 
Similarly, Freemerman et. al. indicated that GLUT1 expression on mononuclear phagocytes 
facilitated their activation and was essential for proinflammatory cytokine production [9]. It 
is possible that these GLUT1-expressing intermediate monocytes contribute to an 
inflammatory state that increases CVD risk in PLWH.
While intermediate monocytes have only recently been defined as a subset of human 
monocytes [15,30], it has become increasingly apparent that this monocyte subset is linked 
to inflammation. A number of inflammatory diseases are selectively associated with the 
intermediate monocyte subset [11,31–33], and recently, intermediate monocytes were shown 
to be the major monocyte subset responsive to low level LPS injection in humans [34]. A 
high level of inflammatory and activation gene expression was identified in the intermediate 
monocyte subset [15], which may explain why this monocyte subset has been linked to 
many inflammatory diseases. However, mechanistic studies are lacking to explain why 
intermediate monocytes can be selectively associated with inflammatory disease.
We did not identify a statistical difference in GLUT1-expressing CD4+ or CD8+ T 
lymphocytes between HIV-infected women with high or low IMT. These results differ from 
some studies examining PLWH that showed an association between CVD and activated T 
lymphocytes [16,17]. However, GLUT1 expression was not examined in those studies. Also, 
our study population consisted of women with lower IMT levels than the noted previous 
studies, which could explain why activated T lymphocytes did not differ between IMT 
groups.
sCD14, sCD163 and IL-6 can be produced by activated monocytes and have been associated 
with IMT in some studies, but most studies show no association between these markers and 
IMT in HIV-infected persons [35]. In our study we found no differences in these markers 
between high and low IMT groups and no correlation was observed between any of the 
markers and GLUT1 intermediate monocytes. It is unclear why sCD14, sCD163 and IL-6 
have only been associated with IMT in a small number of studies. Different study 
populations may explain the discrepant results. It is surprising that GLUT1 expressing 
intermediate monocytes are not correlated with sCD14, sCD163, or IL-6 as GLUT1 is 
associated with monocyte activation. It is possible that monocyte production of sCD14, 
sCD163 and IL-6 occurs through a pathway(s) independently of GLUT1 expression.
In summary, our data suggest a role for GLUT1-expressing intermediate monocytes in 
subclinical CVD observed during HIV infection. Pending replication, GLUT1-expressing 
intermediate monocytes could provide a way to predict CVD events in PLWH and may be a 
useful target for therapy to limit chronic immune activation and inflammation observed 
during HIV infection.
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Figure 1. Monocyte and T lymphocyte expression of GLUT1 and CD38 from women with high 
IMT and low IMT
Monocyte and T lymphocyte populations were identified by flow cytometry as described in 
the Methods. The percentage of (A) monocyte and (B) T lymphocyte populations expressing 
GLUT1. The MFI of GLUT1 on the cell surface of (C) monocytes and (D) T lymphocytes. 
The percentage of (E) monocyte and (F) T lymphocyte populations expressing CD38. The 
percentage of (G) monocyte and (H) T lymphocyte populations expressing GLUT1 and 
CD38. Open circles represent women not on antiretroviral therapy at the time of sample 
collection.
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Table 1
Clinical Characteristics of Study Groups
Variables N Groups p
High IMT Low IMT
Mean Age ± SD, years 30 51.48 ± 6.14 51.68 ± 6.97 0.934
Race (Black) % 30 60 60
Median CD4 Count (IQR), cells/mm3 30 638 (244 - 793) 630 (441 - 917) 0.675
Median CD8 Count (IQR), cells/mm3 30 764 (550 - 1108) 719 (592 - 1122) 0.488
Median CD4/CD8 Ratio (IQR) 30 0.6 (0.3 – 1.2) 0.9 (0.5 – 1.3) 0.272
Viral Load (< 50 copies/mL), % 28 100 73 0.102
Smoking (Current Smokers) % 30 60 60
Median BIF-IMT (IQR), mm 30 0.984 (0.941 - 1.184) 0.701 (0.643 - 0.740) < 0.0001
Median CCA-IMT (IQR), mm 30 0.893 (0.843 – 1.001) 0.653 (0.642 – 0.692) < 0.0001
Median Systolic BP (IQR), mmHg 30 126 (113 – 140) 114 (105 – 122) 0.036
Median Diastolic BP (IQR), mmHg 30 72 (66 – 80) 71 (69 – 76) 0.472
Median Triglycerides (IQR), mg/dL 28 138.5 (101.5 - 164.5) 91.5 (86.25 - 149.5) 0.043
Median Cholesterol (IQR), mg/dL 28 191.5 (162.0 - 202.5) 184.5 (135.5 - 237.0) 0.473
Median HDL (IQR), mg/dL 28 50.0 (42.3 - 59.5) 60.5 (47.8 - 82.8) 0.037
Median LDL (IQR), mg/dL 28 110.0 (79.5 - 126.8) 110.0 (65.5 - 136.3) 0.424
Median Plasma Glucose (IQR), mg/dL 26 90.50 (87.75 - 107.00) 95.00 (85.75 - 97.75) 0.485
Median Hemoglobin A1c (IQR), % 29 6.00 (5.50 - 6.20) 5.45 (5.28 - 5.80) 0.022
Median Serum Insulin (IQR), mIU/mL 19 19.50 (10.75 - 25.50) 13.00 (6.00 - 16.00) 0.039
Median IL-6 (IQR), pg/mL 30 1.005 (0.599 - 1.223) 0.917 (0.609 - 1.485) 0.479
Median sCD14 (IQR), ng/mL 30 2330 (2075 – 3035) 2286 (1968 – 2508) 0.360
Median sCD163 (IQR), ng/mL 30 756.4 (403.2 - 1201) 732.0 (474.6 - 1206) 0.403
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